Internal Medicine

Medicine & Life Sciences

1. Korea 100%
2. Registries 92%
3. Stents 85%
4. Myocardial Infarction 75%
5. Percutaneous Coronary Intervention 75%
6. Heart Failure 64%
7. Drug-Eluting Stents 59%
8. Multicenter Studies 51%
9. Fibrosis 49%
10. Type 2 Diabetes Mellitus 44%
11. Liver 44%
12. Portal Hypertension 43%
13. ST Elevation Myocardial Infarction 41%
14. Safety 39%
15. Confidence Intervals 38%
16. Mortality 38%
17. Therapeutics 38%
18. Liver Cirrhosis 35%
19. Venous Pressure 31%
20. zotarolimus 30%
21. Hemorrhage 29%
22. Sirolimus 28%
23. Mesenchymal Stem Cells 28%
24. Metabolic Syndrome 27%
25. Republic of Korea 26%
26. Diabetic Nephropathies 26%
27. Colonoscopy 26%
28. Serum 26%
29. Blood Pressure 25%
30. Odds Ratio 25%
31. Everolimus 24%
32. Colorectal Neoplasms 22%
33. Prospective Studies 21%
34. Brain Natriuretic Peptide 21%
35. Amlodipine 21%
36. Guidelines 20%
37. Incidence 19%
38. Chronic Hepatitis B 19%
39. Insulin Resistance 19%
40. Stomach 19%
41. Placebos 18%
42. Paclitaxel 18%
43. Propensity Score 18%
44. Human Influenza 17%
45. Kidney 17%
46. Polyps 17%
47. Liver Diseases 17%
48. Thrombosis 17%
49. Population 17%
50. Acute Coronary Syndrome 17%
51. Clopidogrel 16%
52. Randomized Controlled Trials 16%
53. Diabetes Mellitus 16%
54. Glucose 16%
55. Radial Artery 16%
56. Hypertension 16%
57. Neoplasms 16%
58. Podocytes 15%
59. Adiponectin 15%
60. Adenoma 15%
61. Cohort Studies 14%
62. Asthma 14%
63. Metformin 14%
64. Hepatocellular Carcinoma 13%
65. Non-alcoholic Fatty Liver Disease 13%
66. Obesity 13%
67. Inbred OLETF Rats 13%
68. Stroke Volume 13%
69. Aspirin 13%
70. Nutrition Surveys 13%
71. Angiotensin Receptor Antagonists 13%
72. Stomach Neoplasms 13%
73. fimasartan 12%
74. Alcoholic Liver Cirrhosis 11%
75. Non-ST Elevated Myocardial Infarction 11%
76. urushiol 11%
77. Multivariate Analysis 11%
78. Bacteremia 11%
79. Ultrasonography 11%
80. Essential Hypertension 11%
81. Sitagliptin Phosphate 11%
82. C-Reactive Protein 10%
83. Losartan 10%
84. End Stage Liver Disease 10%
85. Elasticity Imaging Techniques 10%
86. 4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one 10%
87. Insulin 10%
88. Rhus 10%
89. Systolic Heart Failure 10%
90. Infections 10%
91. Coronary Angiography 10%
92. Hepatitis 10%
93. Survival 10%
94. Portal Pressure 10%
95. Fasting 10%
96. Chronic Disease 9%
97. Meta-Analysis 9%
98. High Fat Diet 9%
99. Blood Platelets 9%
100. Atrial Fibrillation 9%